Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
KemPharm, Inc.
Financial Advisor (Buy side)
-
$125m
Amryt Pharma plc
Lead Financial Advisor (Recapitalization)
-
US$1.2b
Environmental Impact Acquisition Corp.
Financial Advisor on Merger with GreenLight Biosciences
-
US$50m
Cardiol Therapeutics, Inc.
Lead Left Bookrunner (Follow-On Offering)
-
US$600m
Ascendis Pharma A/S
Co-Manager (Follow-On)
-
US$73m
Rani Therapeutics
Joint Bookrunner (IPO)
-
US$56m
Celcuity, Inc.
Lead Manager (Follow-on)
-
$183.9m
GH Research Ireland
Lead Manager (IPO)
-
US$160m
GH Research PLC
Lead Manager (IPO)